Predictive Role of Ki-67 and Proliferative-Cell Nuclear Antigen (PCNA) in Recurrent Cholesteatoma.

OBJECTIVES To investigate the potential use of Ki-67 and pronuclear cell antigen (PCNA) as indicators of recurrent cholesteatoma. MATERIAL AND METHODS Patients who had been diagnosed with cholesteatoma and who had undergone canal wall-down mastoidectomy were included in this study. Subjects were divided into two groups: recurrent and non-recurrent (i.e., cases without recurrence for at least 2 years). Ossicular pathologies were recorded. Histopathologic specimens were stained for Ki-67 and PCNA and the percentages of stained cells were calculated. RESULTS Neither group demonstrated a significant difference in terms of total Ki-67 per cell, Ki-67-stained cell counts, Ki-67-staining percentages, total PCNA per cell, PCNA-stained cell counts, or PCNA-staining percentages (p>0.05). No significant relationship was noted between the staining percentages for either Ki-67 or PCNA and the incudostapedial involvement (p>0.05); however, a significant relationship was noted between Ki-67 staining and malleus involvement (p<0.05). CONCLUSION Although the recurrent and non-recurrent cholesteatoma groups showed no significant differences in terms of the percentages of stained cells for either Ki-67 or PCNA, we detected high Ki-67 staining in the malleus involvement group. We concluded that cell-proliferation markers could not be defined as indicators of recurrence of cholesteatoma, but they could be defined as indicators of destructive patterns of this disease.

[1]  S. Xie,et al.  The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma , 2017, European Archives of Oto-Rhino-Laryngology.

[2]  T. Ovesen,et al.  Incidence, 10-year recidivism rate and prognostic factors for cholesteatoma , 2017, The Journal of Laryngology &#x0026; Otology.

[3]  K. Sakurai,et al.  Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity , 2017, Clinical and experimental otorhinolaryngology.

[4]  K. Srinivas,et al.  ACQUIRED CHOLESTEATOMA IN CHILDREN AND ADULTS - A CLINICO-PATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY OF ITS CHARACTERISTICS , 2017 .

[5]  S. Xie,et al.  Acquired cholesteatoma epithelial hyperproliferation: Roles of cell proliferation signal pathways , 2016, The Laryngoscope.

[6]  W. Grolman,et al.  The disease recurrence rate after the canal wall up or canal wall down technique in adults , 2016, The Laryngoscope.

[7]  E. Özer,et al.  Analysis of histopathological aspects and bone destruction characteristics in acquired middle ear cholesteatoma of pediatric and adult patients. , 2016, International journal of pediatric otorhinolaryngology.

[8]  Brandon A Mccutcheon,et al.  Surgical Technique and Recurrence in Cholesteatoma: A Meta-Analysis , 2013, Audiology and Neurotology.

[9]  D. Preciado,et al.  The role of inhibitor of DNA‐binding (Id1) in hyperproliferation of keratinocytes: the pathological basis for middle ear cholesteatoma from chronic otitis media , 2010, Cell proliferation.

[10]  Jizhen Lin,et al.  Identification of Id1 in acquired middle ear cholesteatoma. , 2008, Archives of otolaryngology--head & neck surgery.

[11]  L. Chyczewskî,et al.  Some markers of proliferative activity in cholesteatoma epithelium in adults. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[12]  S. Schraff,et al.  Pediatric Cholesteatoma: A Retrospective Review , 2004 .

[13]  A. Desaulty,et al.  Aggressiveness and Quantification of Epithelial Proliferation of Middle Ear Cholesteatoma by MIB1 , 2003, The Laryngoscope.

[14]  R. Kiss,et al.  Detection of Macrophage Migration Inhibitory Factor (MIF) in Human Cholesteatomas and Functional Implications of Correlations to Recurrence Status and to Expression of Matrix Metalloproteinases‐3/9, Retinoic Acid Receptor‐β, and Anti‐apoptotic Galectin‐3 , 2001, The Laryngoscope.

[15]  T. Paunesku,et al.  Proliferating cell nuclear antigen (PCNA): ringmaster of the genome , 2001, International journal of radiation biology.

[16]  R. Kiss,et al.  Determination of the Levels of Expression of Sarcolectin and Calcyclin and of the Percentages of Apoptotic But Not Proliferating Cells to Enable Distinction Between Recurrent and Nonrecurrent Cholesteatomas , 1999, The Laryngoscope.

[17]  E. Kastenbauer,et al.  Epidermal growth factor receptor (EGF-R) in human middle ear cholesteatoma: an analysis of protein production and gene expression. , 1996, The American journal of otology.

[18]  M. Paksoy,et al.  [Evaluation of Ki-67 expression in recurrent cases of cholesteatoma]. , 2007, Kulak burun bogaz ihtisas dergisi : KBB = Journal of ear, nose, and throat.

[19]  Y. Choung,et al.  Original contributions Nucleoplasm staining patterns and cell cycle-associated expression of Ki-67 in middle ear cholesteatoma , 2005 .

[20]  Y. Hishikawa,et al.  Possible Involvement of Keratinocyte Growth Factor and Its Receptor in Enhanced Epithelial-Cell Proliferation and Acquired Recurrence of Middle-Ear Cholesteatoma , 2003, Laboratory Investigation.